Related Experiment Video

Updated: Apr 17, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

45.2K

Building a roadmap for developing combination therapies for Alzheimer's disease

Daniel Perry1, Reisa Sperling, Russell Katz

  • 1Alliance for Aging Research, Washington, DC, USA.

Expert Review of Neurotherapeutics
|February 25, 2015
PubMed

Insights

Combination therapy shows promise for intractable diseases. Experts are exploring combination treatments for Alzheimer's disease, focusing on clinical trial design challenges and creating a roadmap for future research.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trial Design

Background:

  • Combination therapy is a proven strategy for managing complex diseases.
  • There is increasing interest in applying combination approaches to Alzheimer's disease treatment.
  • Key stakeholders from academia, industry, and advocacy groups are involved.

Purpose of the Study:

  • To address the challenges in designing clinical trials for combination therapies in Alzheimer's disease.
  • To outline a roadmap for the successful implementation of such trials.

Main Methods:

  • A co-hosted meeting involving the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute, and the Alzheimer's Association.
  • Discussion and identification of key challenges in clinical trial design for combination treatments.

Main Results:

  • Identified significant hurdles in developing and executing clinical trials for combination Alzheimer's disease therapies.
  • Established a preliminary roadmap to guide future research and development.

Conclusions:

  • Overcoming clinical trial design challenges is crucial for advancing combination therapy for Alzheimer's disease.
  • A collaborative roadmap is essential for facilitating the development of effective combination treatments.
Keywords:
Alzheimer’ diseaseco-developmentcollaborationcombination therapynovel therapy

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.8K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.8K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
914
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
418
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.9K